The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Biweekly combination therapy with gemcitabine and carboplatin compared with gemcitabine monotherapy in patients over 80 years old with advanced non-small-cell lung cancer: Subgroup analysis of the prospective randomized phase II study.
Hideki Kusagaya
No relevant relationships to disclose
Naoki Inui
No relevant relationships to disclose
Masato Karayama
No relevant relationships to disclose
Yuichi Ozawa
No relevant relationships to disclose
Yutaro Nakamura
No relevant relationships to disclose
Shigeki Kuroishi
No relevant relationships to disclose
Koshi Yokomura
No relevant relationships to disclose
MIkio Toyoshima
No relevant relationships to disclose
Toshihiro Shirai
No relevant relationships to disclose
Masafumi Masuda
No relevant relationships to disclose
Takashi Yamada
No relevant relationships to disclose
Kazumasa Yasuda
No relevant relationships to disclose
Takafumi Suda
No relevant relationships to disclose
Kingo Chida
No relevant relationships to disclose